{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:12Z","timestamp":1792928832360,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Kite, a Gilead Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-01102-1","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:02:44Z","timestamp":1767607364000},"page":"304-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-7813","authenticated-orcid":false,"given":"Matthew","family":"Ulrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Milletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"1102_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1102_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125, 22\u201332 (2015).","journal-title":"Blood"},{"key":"1102_CR4","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel) suspension for intravenous fusion. Highlights of Prescribing Information. (Kite Pharma, 2025); https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf"},{"key":"1102_CR5","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"1102_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1102_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081\u20131085 (2021).","journal-title":"Blood"},{"key":"1102_CR8","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1102_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1102_CR10","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2022","unstructured":"Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3\u2009\u00d7\u2009CD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J. Clin. Oncol. 41, 2238\u20132247 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1102_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01488-4","volume":"16","author":"X Liu","year":"2023","unstructured":"Liu, X., Zhao, J., Guo, X. & Song, Y. CD20\u2009\u00d7\u2009CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J. Hematol. Oncol. 16, 90 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1102_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2141.2010.08297.x","volume":"151","author":"K Mihara","year":"2010","unstructured":"Mihara, K. et al. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br. J. Haematol. 151, 37\u201346 (2010).","journal-title":"Br. J. Haematol."},{"key":"1102_CR13","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.4049\/jimmunol.180.6.3739","volume":"180","author":"MTM Vossen","year":"2008","unstructured":"Vossen, M. T. M. et al. CD27 defines phenotypically and functionally different human NK cell subsets. J. Immunol. 180, 3739\u20133745 (2008).","journal-title":"J. Immunol."},{"key":"1102_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.exphem.2008.10.011","volume":"37","author":"C Stoeckle","year":"2009","unstructured":"Stoeckle, C. et al. Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs. Exp. Hematol. 37, 266\u2013275 (2009).","journal-title":"Exp. Hematol."},{"key":"1102_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/696578","volume":"2015","author":"M Croce","year":"2015","unstructured":"Croce, M., Rigo, V. & Ferrini, S. IL-21: a pleiotropic cytokine with potential applications in oncology. J. Immunol. Res. 2015, 696578 (2015).","journal-title":"J. Immunol. Res."},{"key":"1102_CR16","doi-asserted-by":"publisher","first-page":"E577","DOI":"10.1073\/pnas.1524677113","volume":"113","author":"JD Dekker","year":"2016","unstructured":"Dekker, J. D. et al. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. Proc. Natl Acad. Sci. USA 113, E577\u2013E586 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1102_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.exphem.2018.01.003","volume":"60","author":"L Quan","year":"2018","unstructured":"Quan, L. et al. BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints. Exp. Hematol. 60, 47\u201356.e41 (2018).","journal-title":"Exp. Hematol."},{"key":"1102_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10238-022-00968-0","volume":"23","author":"R Maffei","year":"2023","unstructured":"Maffei, R. et al. The dynamic functions of IRF4 in B cell malignancies. Clin. Exp. Med. 23, 1171\u20131180 (2023).","journal-title":"Clin. Exp. Med."},{"key":"1102_CR19","doi-asserted-by":"publisher","first-page":"846357","DOI":"10.3389\/fendo.2022.846357","volume":"13","author":"J Yan","year":"2022","unstructured":"Yan, J. et al. Identification and validation of a prognostic prediction model in diffuse large B-cell lymphoma. Front. Endocrinol. 13, 846357 (2022).","journal-title":"Front. Endocrinol."},{"key":"1102_CR20","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/ajcp\/aqaa161.333","volume":"154","author":"C Li","year":"2020","unstructured":"Li, C., Teruya, B., Bhavana, D. & Althof, P. Large B-cell lymphoma with IRF4 rearrangement involving lung. Am. J. Clin. Pathol. 154, S152\u2013S153 (2020).","journal-title":"Am. J. Clin. Pathol."},{"key":"1102_CR21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1126\/science.286.5446.1949","volume":"286","author":"R Pappu","year":"1999","unstructured":"Pappu, R. et al. Requirement for B cell linker protein (BLNK) in B cell development. Science 286, 1949\u20131954 (1999).","journal-title":"Science"},{"key":"1102_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto, S. et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21\u201333 (2024).","journal-title":"Blood Cancer Discov."},{"key":"1102_CR23","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"1102_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4172\/1948-5956.1000373","volume":"7","author":"V Singh","year":"2015","unstructured":"Singh, V., Gupta, D. & Almasan, A. Development of novel anti-CD20 monoclonal antibodies and modulation in CD20 levels on cell surface: looking to improve immunotherapy response. J. Cancer Sci. Ther. 7, 347\u2013358 (2015).","journal-title":"J. Cancer Sci. Ther."},{"key":"1102_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","volume":"13","author":"SM Larson","year":"2023","unstructured":"Larson, S. M. et al. CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma. Cancer Discov. 13, 580\u2013597 (2023).","journal-title":"Cancer Discov."},{"key":"1102_CR26","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569\u20131575 (2020).","journal-title":"Nat. Med."},{"key":"1102_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"1102_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp, M. S. et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 195, 388\u2013398 (2021).","journal-title":"Br. J. Haematol."},{"key":"1102_CR29","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690\u2013700 (2021).","journal-title":"Br. J. Haematol."},{"key":"1102_CR30","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.21.00377","volume":"39","author":"MJ Frank","year":"2021","unstructured":"Frank, M. J. et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J. Clin. Oncol. 39, 3034\u20133043 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1102_CR31","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1200\/JCO.2023.41.16_suppl.7547","volume":"41","author":"B Miles","year":"2023","unstructured":"Miles, B. et al. Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). J. Clin. Oncol. 41, 7547 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1102_CR32","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 39, 1537\u20131547 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1102_CR33","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.01.42","volume":"7","author":"C Lo Nigro","year":"2019","unstructured":"Lo Nigro, C. et al. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann. Transl. Med. 7, 105 (2019).","journal-title":"Ann. Transl. Med."},{"key":"1102_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","volume":"30","author":"N Lam","year":"2023","unstructured":"Lam, N. et al. Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions. Mol. Ther. Oncolytics 30, 132\u2013149 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1102_CR35","first-page":"2470","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie, C. et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood 141, 2470\u20132482 (2023).","journal-title":"Blood"},{"key":"1102_CR36","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong, C. et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood 136, 1632\u20131644 (2020).","journal-title":"Blood"},{"key":"1102_CR37","doi-asserted-by":"crossref","unstructured":"Nastoupil, L. J. et al. KITE-363: A phase 1 study of an autologous anti-CD19\/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed\/refractory (R\/R) B-cell lymphoma (BCL). J. Clin. Oncol. 40, TPS7579 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7579"},{"key":"1102_CR38","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1102_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285\u2013295 (2017).","journal-title":"Mol. Ther."},{"key":"1102_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803\u20131813 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1102_CR41","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1102_CR42","doi-asserted-by":"publisher","unstructured":"Kite, a Gilead Company. Tumor transcriptomic profiling of tissue biopsies from patients in ZUMA-14. Zenodo https:\/\/doi.org\/10.5281\/zenodo.16809020 (2025).","DOI":"10.5281\/zenodo.16809020"},{"key":"1102_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01102-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:02:59Z","timestamp":1772204579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01102-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.Strati reports consultancy for Kite, Roche-Genentech, Hutchison MediPharma, ADC Therapeutics, Incyte Morphosis and TG Therapeutics and research funding from Sobi Pharmaceuticals, AstraZeneca-Acerta, ALX Oncology and ADC Therapeutics. L.L. reports consultancy for and travel support from AbbVie, AstraZeneca, Merck, TG Therapeutics, Janssen, Epizyme, Kite, Celgene, Pharmacyclics, Bristol Myers Squibb, ADC Therapeutics, BeiGene and Seattle Genetics, speakers\u2019 bureau participation for and travel support from Kite, BeiGene, Pharmacyclics, Janssen, AstraZeneca, Seattle Genetics, TG Therapeutics, Epizyme, Karyopharm, Celgene and Bristol Myers Squibb and participation on the data safety advisory board for TG Therapeutics, AbbVie, Pharmacyclics, Janssen, AstraZeneca, Seattle Genetics and ADC Therapeutics. P.Shiraz reports research funding from Kite and Orca Bio. L.E.B. reports honoraria from Kite, a consultancy or advisory role for Kite, Gilead and Roche, speakers\u2019 bureau participation for Kite and AstraZeneca and research funding from MustangBio, Merck, Amgen and AstraZeneca. O.O.O. reports a consultancy or advisory role for Kite, Janssen, Pfizer, Novartis and Curio Science and honoraria and research funding from Kite. M.U. reports advisory board participation for Gilead and Stemline. A.R. reports honoraria from Cigna, Amgen and Takeda, a consultancy or advisory role for Amgen, AstraZeneca, GenMab, Novartis and Takeda and speakers\u2019 bureau participation for Takeda. T.Z. and J.S. report employment with Kite. F.M. reports employment with and research funding from Kite and Gilead and stock or other ownership in Gilead. J.K. and H.X. report employment with Kite and stock or other ownership in Gilead. R.S. reports employment and leadership role with Kite and Atara, stock or other ownership in Gilead and Atara and patents, royalties and other intellectual property from Kite. F.N. reports prior employment with Kite and stock or other ownership in Gilead. K.P. reports consultancy for AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Fate Therapeutics, Genentech\/Roche, Janssen\/Pharmacyclics, Kite, Lilly\/Loxo Oncology, Merck, MorphoSys, Sana Pharma and Xencor, research funding (to institution) from AbbVie, Adaptive Biotechnologies, Adicet Bio, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Cargo Therapeutics, Fate Therapeutics, Genentech\/Roche, Janssen\/Pharmacyclics, Kite, Lilly\/Loxo Oncology, Merck, Nurix, Sana Pharma and Xencor and speakers\u2019 bureau participation for AstraZeneca, Bristol Myers Squibb and Kite.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}